This review will summarize the current standard of care; key issues that arise when treating patients with HER2-positive disease; and developments in novel therapeutics, including small-molecule inhibitors, nanoparticles, immunotherapy, and agents targeting resistance pathways.
|Original language||English (US)|
|Journal||ONCOLOGY (United States)|
|State||Published - Feb 15 2016|
ASJC Scopus subject areas
- Cancer Research